Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors

Melanoma Research
Alexander ThiemAnja Gesierich

Abstract

Anti-PD-1 targeted immunotherapies have revolutionized the treatment of advanced melanoma and other tumor entities, and long disease-free intervals have been reported in responding patients. However, a considerable number of patients still progress rapidly after the start of anti-PD-1 antibodies. Here, we document two patients, 78 and 85-year old, who suffered from advanced BRAF-V600 wild-type melanoma and received pembrolizumab 2 mg/kg every 3 weeks as the first systemic treatment. After only one, respectively, two infusions of pembrolizumab, both patients developed melanuria and diffuse melanosis cutis (DMC) on sun-exposed areas of their skin. Both also had liver metastases, which have been reported to be associated with DMC before. Pembrolizumab was stopped because of rapid tumor progression and both patients died within 2 months after manifestation of DMC. We conclude that DMC is a condition that may be a negative predictor of response to anti-PD-1 treatment. With respect to the very short survival, which is even shorter than that reported after conventional therapies, it needs to be evaluated whether immunotherapy may be a (relative) contraindication in DMC patients when another treatment option, that is targeted therapy, ...Continue Reading

References

Mar 1, 1954·The Journal of Investigative Dermatology·G T WILSON
Feb 27, 2004·Journal of Cutaneous Pathology·Klaus J BusamPaul Chapman
Apr 28, 2010·Clinica Chimica Acta; International Journal of Clinical Chemistry·Dzeneta Nezirević DernrothBertil Kågedal
Dec 12, 2012·Journal of the American Academy of Dermatology·Deshan F SebaratnamDédée F Murrell
Aug 28, 2014·The Australasian Journal of Dermatology·Rashi MinochaPablo Fernández-Peñas
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Feb 16, 2016·The British Journal of Dermatology·K StaserR C Fields
May 18, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ricardo E VilainRichard A Scolyer

❮ Previous
Next ❯

Citations

Apr 20, 2021·Journal of Pain and Symptom Management·Diane PortmanKristine A Donovan
Jul 25, 2021·Journal of Clinical Medicine·Lorenza BurziSimone Ribero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Recenti progressi in medicina
Francesco Spagnolo
Dermatology : International Journal for Clinical and Investigative Dermatology
Maja HofmannUwe Trefzer
© 2022 Meta ULC. All rights reserved